目的 探討血塞通注射液治療急性腦梗死恢復(fù)期患者（瘀血阻滯型）的臨床療效。方法 選取2018年2月—2020年3月南陽市中心醫(yī)院收治的98例腦梗死恢復(fù)期（瘀血阻滯型）患者，隨機分為對照組和治療組，每組各49例。對照組給予西醫(yī)常規(guī)治療，治療組在對照組基礎(chǔ)上靜脈滴注血塞通注射液，0.4 g/次，1次/d。兩組均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組神經(jīng)功能（NIHSS）評分、SS-QOL量表評分、超敏C反應(yīng)蛋白（hs-CRP）、同型半胱氨酸（Hcy）、基質(zhì)金屬蛋白酶-2（MMP-2）、基質(zhì)細胞衍生因子-1（SDF-1）、血管內(nèi)皮生長因子（VEGF）、S100蛋白（S100B）、血紅素加氧酶（HO-1）、內(nèi)皮祖細胞（EPCs）的變化情況。結(jié)果 治療后，治療組總有效率93.88%，顯著高于對照組的73.47%（P<0.05）。治療后，兩組NIHSS評分顯著降低，但SS-QOL評分則升高（P<0.05）；治療后，治療組NIHSS評分低于對照組，但SS-QOL評分高于對照組（P<0.05）。治療后，兩組Hs-CRP、Hcy、MMP-2均顯著降低（P<0.05）；治療后，治療組Hs-CRP、Hcy、MMP-2低于對照組（P<0.05）。治療后兩組VEGF、SDF-1水平均顯著降低（P<0.05）；治療后，治療組VEGF、SDF-1水平低于對照組（P<0.05）。治療后兩組血清S100B均降低，但HO-1、EPCs較前升高（P<0.05）；治療后，治療組S100B低于對照組，但HO-1、EPCs高于對照組（P<0.05）。結(jié)論 血塞通注射液治療瘀血阻滯型急性腦梗死恢復(fù)期患者具有較好的臨床療效，促進神經(jīng)功能修復(fù)，減輕缺血再灌注傷，有助于促進側(cè)枝循環(huán)形成，提高抗氧化能力，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Xuesaitong Injection in treatment of acute cerebral infarction in recovery stage (blood stasis block type). Methods A total of 98 patients with cerebral infarction in recovery stage (blood stasis type) admitted to Nanyang Central Hospital from February 2018 to March 2020 were selected and randomly divided into control group and treatment group, 49 patients in each group. The control group was given conventional western medicine treatment. Patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 0.4 g/time, once daily. Both groups were treated continuously for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of NIHSS score, SS-QOL score, hs-CRP, Hcy, MMP-2, VEGF, SDF-1, S100B, HO-1, and EPCs in two groups were compared. Results After treatment, the total effective rate of the treatment group was 93.88%, significantly higher than that of the control group (73.47%, P<0.05). After treatment, NIHSS score was significantly decreased in both groups, but SS-QOL score was increased (P<0.05). After treatment, the NIHSS score of the treatment group was lower than that of the control group, but the SS-QOL score was higher than that of the control group (P<0.05). After treatment, hs-CRP, Hcy and MMP-2 in two groups were significantly decreased (P<0.05). After treatment, hs-CRP, Hcy and MMP-2 in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of VEGF and SDF-1 in two groups were significantly decreased (P<0.05). After treatment, the levels of VEGF and SDF-1 in treatment group were lower than those in control group (P<0.05). After treatment, serum S100B was decreased in both groups, but HO-1 and EPCs were increased (P<0.05). After treatment, S100B in the treatment group was lower than that in the control group, but HO-1 and EPCs in the treatment group were higher than that in the control group (P<0.05). Conclusion Xuesaitong Injection has good clinical efficacy in treatment of acute cerebral infarction in recovery stage (blood stasis block type), and can promotes nerve function repair, reduces ischemia reperfusion injury, and also can help to promote the formation of collateral circulation, improves antioxidant capacity, which has certain clinical application value.

R971

南陽市科技攻關(guān)計劃項目（KJGG2018082）